Addition of Rifampin to Standard Therapy for Treatment of Native Valve Infective Endocarditis Caused by Staphylococcus aureus
Open accessThe DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Staphylococcus aureus is a common cause of native valve infective endocarditis (IE). Rifampin is often added to traditional therapy for the management of serious S. aureus infections. There are no large, prospective studies documenting the safety and efficacy of adjunctive therapy with rifampin for treatment of native valve S. aureus IE. We reviewed all cases of definite native valve S. aureus IE confirmed by modified Duke criteria in a large urban hospital between 1 January 2004 and 31 December 2005. A retrospective cohort analysis was used to assess the impact of the addition of rifampin to standard therapy. There were 42 cases of S. aureus IE treated with the addition of rifampin and 42 controls. Cases received a median of 20 days of rifampin (range, 14 to 48 days). Rifampin-resistant S. aureus isolates developed in nine cases who received rifampin before clearance of bacteremia (56%), while significant hepatic transaminase elevations also occurred in nine cases, all of whom had hepatitis C infection. Unrecognized significant drug-drug interactions with rifampin occurred frequently (52%). Cases were more likely to have a longer duration of bacteremia (5.2 versus 2.1 days; P < 0.001) and were less likely to survive (79% versus 95%; P = 0.048) than controls. Our results suggest that the potential for hepatotoxicity, drug-drug interactions, and the emergence of resistant S. aureus isolates warrants a careful risk-benefit assessment before adding rifampin to standard antibiotic treatment of native valve S. aureus IE until further clinical studies are performed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, use of rifampin as adjunct therapy for S aureus NVE has been associated with higher rates of adverse events (primarily hepatotoxicity) and a significantly lower survival rate.162”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis
Li, J. S., Sexton, D. J., Mick, N., Nettles, R., Fowler, V. G., Ryan, T., Bashore, T., & Corey, G. R. (2000) · Clinical Infectious Diseases · doi:10.1086/313753 · Cited by 4,027 · cited 4×
“All cases and controls had definite S. aureus IE based on the modified Duke criteria ( 19 ).”
MethodInfluentialKlevens, R. M. (2007) · JAMA · doi:10.1001/jama.298.15.1763 · Cited by 3,726 · cited 1×
“While S. aureus IE has long been associated with significant morbidity and mortality (8, 23, 25), its management is now further complicated by the rising incidence of methicillin-resistant S. aureus (MRSA) strains causing disease ( 16 ), as well as the limited treatment options for MRSA (17, 22).”
BackgroundBaddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.165564 · Cited by 1,707
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459 · cited 1×
“003 Right and left sided 3 (7) 9 (21) 0.”
Self-citationStaphylococcus aureus Endocarditis: A Consequence of Medical Progress
Fowler, V. G., Miro, J. M., Hoen, B., Cabell, C. H., Abrutyn, E., Rubinstein, E., Corey, G. R., Spelman, D., Bradley, S. F., Barsic, B., et al. (2005) · JAMA · doi:10.1001/jama.293.24.3012 · Cited by 1,174 · cited 2×
“aureus IE has long been associated with significant morbidity and mortality (8, 23, 25), its management is now further complicated by the rising incidence of methicillin-resistant S.”
BackgroundResistance to Antibiotics Mediated by Target Alterations
Spratt, B. G. (1994) · Science · doi:10.1126/science.8153626 · Cited by 674 · cited 2×
“aureus infections (15, 28), and it has recently been shown at the genetic level to occur after only a single dose of rifampin in a patient with MRSA endocarditis (24).”
BackgroundLevine, D. P., Fromm, B. S., & Reddy, B. R. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-9-674 · Cited by 577 · cited 4×
“(18) also showed that rifampin plus vancomycin was no better than vancomycin alone for treatment of MRSA IE, though that trial was likely underpowered to detect a true difference.”
BackgroundInfluentialMwangi, M. M., Wu, S. W., Zhou, Y., Sieradzki, K., de Lencastre, H., Richardson, P., Bruce, D., Rubin, E., Myers, E., Siggia, E. D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609839104 · Cited by 538 · cited 2×
“aureus infections (15, 28), and it has recently been shown at the genetic level to occur after only a single dose of rifampin in a patient with MRSA endocarditis (24).”
BackgroundHowden, B. P., Ward, P. B., Charles, P. G. P., Korman, T. M., Fuller, A., Cros, P. D., Grabsch, E. A., Roberts, S. A., Robson, J., Read, K., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/381202 · Cited by 484 · cited 1×
“(%) Central nervous system 14 (33) 6 (14) 0.”
Fibroblasts Can Be Genetically Modified to Produce Excitable Cells Capable of Electrical Coupling
Kizana, E., Ginn, S. L., Allen, D. G., Ross, D. L., & Alexander, I. E. (2005) · Circulation · doi:10.1161/01.cir.0000153812.64956.ef · Cited by 382
Miro, J. M., Anguera, I., Cabell, C. H., Chen, A. Y., Stafford, J. A., Corey, G. R., Olaison, L., Eykyn, S., Hoen, B., Abrutyn, E., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/431979 · Cited by 334 · cited 1×
“While S. aureus IE has long been associated with significant morbidity and mortality (8, 23 , 25), its management is now further complicated by the rising incidence of methicillin-resistant S. aureus (MRSA) strains causing disease (16), as well as the limited treatment options for MRSA (17, 22).”
BackgroundHeldman, A. W., Hartert, T. V., Ray, S. C., Daoud, E. G., Kowalski, T. E., Pompili, V. J., Sisson, S. D., Tidmore, W. C., vom Eigen, K. A., Goodman, S. N., et al. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00070-8 · Cited by 289 · cited 1×
“aureus IE in injection drug users (4, 13).”
BackgroundRifampin and Rifabutin Drug Interactions: An Update
Finch, C. K., Chrisman, C. R., Baciewicz, A. M., & Self, T. H. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.9.985 · Cited by 233
Grosset, J., & Leventis, S. (1983) · Clinical Infectious Diseases · doi:10.1093/clinids/5.supplement_3.s440 · Cited by 218 · cited 1×
“Rifampin has numerous potential adverse effects, including anaphylaxis, gastrointestinal symptoms, hemolytic anemia, thrombocytopenia, acute renal failure, uveitis, and rash, in addition to hepatic toxicity (9, 30).”
BackgroundMicek, S. T. (2007) · Clinical Infectious Diseases · doi:10.1086/519471 · Cited by 202 · cited 9×
“Lastly, resistance to rifampin can develop rapidly in S. aureus (15, 28), and this process has been characterized at the genetic level after a single dose of rifampin for an MRSA isolate (24).”
BackgroundInfluentialKaye, K. S., Engemann, J. J., Fraimow, H. S., & Abrutyn, E. (2004) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2004.04.003 · Cited by 188 · cited 3×
“The development of S. aureus isolates resistant to rifampin is a well-recognized disadvantage of its use for S. aureus infections ( 15 , 28), and it has recently been shown at the genetic level to occur after only a single dose of rifampin in a patient with MRSA endocarditis (24).”
BackgroundInfluentialLimitations of Vancomycin in the Management of Resistant Staphylococcal Infections
Kollef, M. H. (2007) · Clinical Infectious Diseases · doi:10.1086/519470 · Cited by 178 · cited 9×
“Lastly, resistance to rifampin can develop rapidly in S. aureus (15, 28), and this process has been characterized at the genetic level after a single dose of rifampin for an MRSA isolate (24).”
BackgroundInfluentialDworkin, R. J., Sande, M. A., Lee, B. L., & Chambers, H. F. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91083-0 · Cited by 170 · cited 1×
“aureus IE in injection drug users (4, 13).”
BackgroundHawkins, C. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.17.1861 · Cited by 166 · cited 1×
“10), although they did not clarify the proportion receiving each drug (12).”
BackgroundStaphylococcus aureus Endocarditis: Combined Therapy With Vancomycin and Rifampin
Faville, R. J. (1978) · JAMA · doi:10.1001/jama.1978.03290180037019 · Cited by 158
(1990) · Infectious Diseases Newsletter · doi:10.1016/0278-2316(90)90059-o · Cited by 151
Chuard, C., Herrmann, M., Vaudaux, P., Waldvogel, F. A., & Lew, D. P. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.12.2611 · Cited by 143 · cited 1×
“aureus (2, 20); (iii) case reports of the benefit of adding rifampin to standard therapy for S.”
BackgroundLucet, J. C., Herrmann, M., Rohner, P., Auckenthaler, R., Waldvogel, F. A., & Lew, D. P. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.12.2312 · Cited by 142 · cited 1×
“aureus (2, 20); (iii) case reports of the benefit of adding rifampin to standard therapy for S.”
BackgroundSchrenzel, J., Harbarth, S., Schockmel, G., Genné, D., Bregenzer, T., Flueckiger, U., Pétignat, C., Jacobs, F., Francioli, P. B., Zimmerli, W., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/424506 · Cited by 136 · cited 2×
“Other studies that have added rifampin to standard therapy have also seen higher incidences of elevated transaminases or hepatitis in the rifampin groups (18, 26).”
BackgroundNadji, G., Rémadi, J. P., Coviaux, F., Ali Mirode, A., Brahim, A., Enriquez-Sarano, M., & Tribouilloy, C. (2005) · Heart · doi:10.1136/hrt.2004.042648 · Cited by 96 · cited 1×
“While S. aureus IE has long been associated with significant morbidity and mortality (8, 23, 25 ), its management is now further complicated by the rising incidence of methicillin-resistant S. aureus (MRSA) strains causing disease (16), as well as the limited treatment options for MRSA (17, 22).”
BackgroundAntistaphylococcal Activity of Rifampin with Other Antibiotics
Zinner, S. H., Lagast, H., & Klastersky, J. (1981) · The Journal of Infectious Diseases · doi:10.1093/infdis/144.4.365 · Cited by 92 · cited 1×
“This possibility has been illustrated in vitro in previous studies with oxacillin (29, 32), nafcillin (10), vancomycin (10, 27), and teicoplanin (10).”
ResultHackbarth, C. J., Chambers, H. F., & Sande, M. A. (1986) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.29.4.611 · Cited by 90 · cited 1×
“This possibility has been illustrated in vitro in previous studies with oxacillin (29, 32), nafcillin (10), vancomycin (10, 27), and teicoplanin (10).”
ResultThe Efficacy of Rifampin as Adjunctive Therapy in Selected Cases of Staphylococcal Endocarditis
Massanari, R. M., & Donta, S. T. (1978) · CHEST Journal · doi:10.1378/chest.73.3.371 · Cited by 85 · cited 3×
“75 End-stage renal disease 9 (21) 11 (26) 0.”
BackgroundShelburne, S. A., Musher, D. M., Hultén, K. G., Ceasar, H., Lu, M. Y., Bhaila, I., & Hamill, R. J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.4016-4019.2004 · Cited by 75 · cited 1×
“This possibility has been illustrated in vitro in previous studies with oxacillin (29, 32), nafcillin (10), vancomycin (10, 27 ), and teicoplanin (10).”
ResultRifampin, a Useful Drug for Nonmycobacterial Infections
Vesely, J. J. K., Pien, F. D., & Pien, B. C. T. (1998) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03861.x · Cited by 43 · cited 1×
“Rifampin has numerous potential adverse effects, including anaphylaxis, gastrointestinal symptoms, hemolytic anemia, thrombocytopenia, acute renal failure, uveitis, and rash, in addition to hepatic toxicity (9, 30).”
BackgroundHageman, J. C., Liedtke, L. A., Sunenshine, R. H., Strausbaugh, L. J., McDonald, L. C., Tenover, F. C., & Infectious Diseases Society of America Emerging Infections Network (2006) · Clinical Infectious Diseases · doi:10.1086/506568 · Cited by 37 · cited 3×
“However, the review by Hawkins et al. (12) and the survey by Hageman et al. ( 11 ) suggest that clinicians are still likely to add rifampin to patients who appear severely ill or have protracted bacteremia.”
BackgroundMethodResultInfluentialYzerman, E. P. F., Boelens, H. A., Vogel, M., & Verbrugh, H. A. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.2.233 · Cited by 28 · cited 1×
“This problem has been noted in other studies in which rifampin was added to standard therapy for serious S. aureus infections (14, 31 ).”
ResultIn Vitro Study of the Combination of Rifampin with Oxacillin Against Staphylococcus aureus
van der Auwera, P., & Klastersky, J. (1983) · Clinical Infectious Diseases · doi:10.1093/clinids/5.supplement_3.s509 · Cited by 20 · cited 1×
“This possibility has been illustrated in vitro in previous studies with oxacillin (29, 32), nafcillin (10), vancomycin (10, 27), and teicoplanin (10).”
ResultOptimizing Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia
Cosgrove, S. E., & Fowler, V. G. (2007) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-2007-996409 · Cited by 14 · cited 1×
“, after clearance of bacteremia) to reduce the risk of developing resistance has not been shown prospectively, but some experts recommend waiting to add rifampin until after blood cultures have cleared (3), and our data support this approach.”
Result
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Habib, G., Lancellotti, P., Antunes, M. J., Bongiorni, M. G., Casalta, J.-P., Del Zotti, F., Dulgheru, R., El Khoury, G., Erba, P. A., Iung, B., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv319 · Cited by 4,997
“Although the level of evidence is poor, adding rifampin to the treatment of staphylococcal PVE is standard practice, although treatment may be associated with microbial resistance, hepatotoxicity and drug interactions.(164)”
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
“aureus endocarditis did not improve outcomes but was associated with hepatic adverse effects, drug interactions, and the emergence of resistance [173].”
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
“ated with higher rates of adverse events (primarily hepatotoxicity) and a significantly lower survival rate.(162) Thus, routine”
BackgroundGuidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009)
Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and by the International Society of Chemotherapy (ISC) for Infection and Cancer, Habib, G., Hoen, B., Tornos, P., Thuny, F., Prendergast, B., Vilacosta, I., Moreillon, P., de Jesus Antunes, M., Thilen, U., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp285 · Cited by 2,014
Metadata
- Authors
- Riedel, D. J., Weekes, E., & Forrest, G. N.
- Affiliations
- University of Maryland, Baltimore (US)
- University of Maryland Medical Center (US)
- Corresponding author
- Riedel, David J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2008-07
- Volume
- 52
- Issue
- 7
- Pages
- 2463-2467
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC2443910
- OpenAlex
- W2145616988
- Cited by
- 136
- References
- 33
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 6 · 2023: 8 · 2022: 4 · 2021: 6 · 2020: 9 · 2019: 7 · 2018: 6 · 2017: 7 · 2016: 4 · 2015: 14 · 2014: 5 · 2013: 10 · 2012: 6
- FWCI
- 9.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Streptococcal Infections and Treatments
- Keywords
- rifampicin, native valve endocarditis, Staphylococcus aureus, adjunctive antibiotic therapy, rifampicin resistance, hepatotoxicity, drug-drug interactions, survival, hepatitis C, risk-benefit assessment
- MeSH terms
- Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents, Drug Interactions, Endocarditis, Bacterial, Female, Heart Valve Diseases, Humans, Liver, Male, Middle Aged, Retrospective Studies, Rifampin, Staphylococcal Infections, Staphylococcus aureus, Cohort Studies, Bacteremia, Drug Resistance, Bacterial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.